Lineage Cell Therapeutics Inc. — Director's Dealing 2017

Aug 23, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Patton Stephana Eilene						2. Issuer Name and Ticker or Trading Symbol BIOTIME INC [ BTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 08/21/2017								X	Director Officer (give title below)		10% Owner Other (specify below)
1010 ATLANTIC AVENUE, SUITE 102 (Street) ALAMEDA CA 94501 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X	General Counsel 6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				Owned	5. Amount of Securities Beneficially Following	(D) or Indirect (I) (Instr. 4)	6. Ownership Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	V	Amount	(A) or (D)		Price		Reported Transaction(s) (Instr. 3 and 4)
Common Shares, no par value 08/21/2017								P		7,500	A		\$2.5835		7,500		D
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	3A. Deemed 4. Execution Date, (Month/Day/Year) 8)		5. Number Transaction of Code (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Date Exercisable Expiration Date Title

Explanation of Responses:

Remarks:

/s/Stephana E. Patton 08/22/2017

Amount or Number of Shares

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

and 5)

Code V (A) (D)